Clinical Trial Update: VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of VRC 705, a Zika virus DNA vaccine, completed to assess safety and immunogenicity in healthy adults and adolescents.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Zika Virus Disease

Drugs mentioned

• VRC 705 (DNA vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Zika Virus, Zika Virus Infection | Phase 2 | Status: COMPLETED | Results posted: 2020-12-04